WO1995001791A2 - Utilisation de l'efaroxan et de ses derives pour la fabrication de medicaments destines au traitement des maladies neurodegeneratives - Google Patents
Utilisation de l'efaroxan et de ses derives pour la fabrication de medicaments destines au traitement des maladies neurodegeneratives Download PDFInfo
- Publication number
- WO1995001791A2 WO1995001791A2 PCT/FR1994/000841 FR9400841W WO9501791A2 WO 1995001791 A2 WO1995001791 A2 WO 1995001791A2 FR 9400841 W FR9400841 W FR 9400841W WO 9501791 A2 WO9501791 A2 WO 9501791A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hydrogen atom
- propyl
- chloro
- alzheimer
- neurodegenerative diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Definitions
- the present invention relates to the use of Efaroxan and its derivatives to obtain a neuroprotective medicament, intended for the treatment of senile dementia of the Alzheimer type, of pre-Alzheimer syndrome, of supra-nuclear progressive paralysis and others neurodegenerative diseases.
- Alzheimer's disease is a progressive neurodegenerative disease affecting particularly but not exclusively the central cholinergic system (Nucleus basalis de Meynert) resulting in a loss of cognitive faculties, a loss of intellectual capacities, behavioral and personality disorders .
- the central cholinergic system Nucleus basalis de Meynert
- Alzheimer's disease There is currently no satisfactory treatment either for the treatment of symptoms or to slow its progression. Diagnosing the disease is difficult, and you can never be sure to diagnose Alzheimer's disease itself. It is in particular the anatomo-histological analysis carried out post-mortem by, among other things, the detection of senile extraneuronal plaques and intraneuronal neurofibrillary tangles, which can allow the disease to be diagnosed without ambiguity. Alzheimer's. It is also associated with loss of cell bodies and depletion of neurotransmitters, in particular acetylcholine. In the absence of this histological and biochemical evidence, the clinical characteristics lead to the diagnosis of a neurodegenerative disease, of the pre-Alzheimer type.
- PSP Progressive Supranuclear Paralysis
- non familia. Appearing late and involving disturbances of several neurotransmitters.
- PSP is characterized by dementia with postural instability, rigidity, bradykinesia associated , accompanied by supranuclear ophthalmoplegia. This disease appears in approximately 4% of patients with Parkinsonism. There is currently no treatment for this disease. Palliative or symptomatological therapies have no satisfactory effect.
- faroxan 2- (2-ethyl-2,3 dihydrobenzo-furanyl) - 2-imidazoli
- This compound is described in patent application GB-2 102 422 as well as its therapeutic application as an antidepressant and antimigraine drug.
- This compound and its derivatives are also described in patent application WO 92/05171 where the action of the levorotatory enantiomer for treating diabetes is demonstrated, as an agent blocking potassium channels.
- the present invention relates to the use of Efaroxan and its derivatives for the preparation of a medicament intended for the treatment of senile dementia of the Alzheimer type, of pre-Alzheimer syndrome, of supra-nuclear progressive paralysis and of other neurodegenerative diseases. - tives.
- Efaroxan and its derivatives is meant the compound of formula I
- R 1 represents a hydrogen atom, a linear or branched C 1 -C 6 alkyl radical
- R 2 represents a hydrogen atom, a methyl, chloro, bromo or fluoro group
- R 3 represents a hydrogen atom, a methyl, hydroxy, methoxy, fluoro, chloro, or bromo group, and its therapeutically acceptable salts, its racemic or its optically active isomers.
- R 2 and R 3 represent a hydrogen atom and R 1 represents an ethyl, n-propyl or i-propyl group.
- the compound of general formula I is chosen from the following compounds:
- Scopolamine a central antagonist, administered before the first training session for passive avoidance behavior, induces a dose-dependent amnesia measurable 48 hours later during a second session.
- the following table shows the effect of Efaroxan in the presence of scopolamine, in a dose-dependent manner, the increase in time that the rat takes to enter from a lit compartment to a dark compartment where it receives a small electric shock.
- the percentage of the effect is indicated in the 3rd column.
- compositions are administered orally in the form of capsules or tablets dosed from 1 to 100 mg of active principle, more particularly from 2, 5 and 20 mg per capsule or by intravenous route in the form of injectable solution dosed with 0.1 10 mg of faroxan.
- Efaroxan has been administered at a dose of 2 to 20 mg per dose per day for 6 months, to patients who have manifested memory problems, the symptoms of cognitive deficits and behavioral disorders suggesting a pre- Alzheimer's.
- the results on the overall symptomatology showed a benefit in 30% of the cases.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69421705T DE69421705T2 (de) | 1993-07-09 | 1994-07-07 | Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen |
EP94921698A EP0707477B1 (de) | 1993-07-09 | 1994-07-07 | Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen |
CA002166781A CA2166781A1 (fr) | 1993-07-09 | 1994-07-07 | Utilisation de l'efaroxan et de ses derives pour la fabrication de medicaments destines au traitement des maladies neurodegeneratives |
AU72308/94A AU688346B2 (en) | 1993-07-09 | 1994-07-07 | Use of efaxoran and its derivatives for the production of drugs for treating neurodegenerative diseases |
US08/581,516 US5661172A (en) | 1993-07-09 | 1994-07-07 | Use of efaroxan and derivatives thereof for the treatment of Alzheimer's disease |
JP50386595A JP3494651B2 (ja) | 1993-07-09 | 1994-07-07 | 神経変性疾患の治療を目的とする医薬生成物の製造のためのエファロキサンおよびその誘導体の使用 |
NZ268914A NZ268914A (en) | 1993-07-09 | 1994-07-07 | Use of efaroxan and derivatives to prepare medicaments for treating neurodegenerative diseases especially alzheimer's disease |
DK94921698T DK0707477T3 (da) | 1993-07-09 | 1994-07-07 | Anvendelse af Efaxoran og derivater deraf til fremstilling af lægemidler beregnet til behandling af neurodegenerative sygdo |
GR20000400227T GR3032531T3 (en) | 1993-07-09 | 2000-02-02 | Use of efaxoran and its derivatives for the production of drugs for treating neurodegenerative diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR93/08497 | 1993-07-09 | ||
FR9308497A FR2707166B1 (fr) | 1993-07-09 | 1993-07-09 | Utilisation de l'efaroxan et de ses dérivés pour la fabrication de médicaments destinés au traitement de maladies neurodégénératives et leur progression . |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1995001791A2 true WO1995001791A2 (fr) | 1995-01-19 |
WO1995001791A3 WO1995001791A3 (fr) | 1995-03-09 |
Family
ID=9449128
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1994/000841 WO1995001791A2 (fr) | 1993-07-09 | 1994-07-07 | Utilisation de l'efaroxan et de ses derives pour la fabrication de medicaments destines au traitement des maladies neurodegeneratives |
Country Status (14)
Country | Link |
---|---|
US (1) | US5661172A (de) |
EP (1) | EP0707477B1 (de) |
JP (1) | JP3494651B2 (de) |
AT (1) | ATE186640T1 (de) |
AU (1) | AU688346B2 (de) |
CA (1) | CA2166781A1 (de) |
DE (1) | DE69421705T2 (de) |
DK (1) | DK0707477T3 (de) |
ES (1) | ES2140544T3 (de) |
FR (1) | FR2707166B1 (de) |
GR (1) | GR3032531T3 (de) |
NZ (1) | NZ268914A (de) |
PT (1) | PT707477E (de) |
WO (1) | WO1995001791A2 (de) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2752163A1 (fr) * | 1996-08-12 | 1998-02-13 | Pf Medicament | Utilisation de l'efaroxan pour la fabricaton de medicament destine au traitement de la maladie de huntington |
US8188126B2 (en) | 2002-05-16 | 2012-05-29 | Pierre Fabre Medicament | Imidazolic compounds and use thereof as alpha-2 adrenergic receptors |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI251813B (en) * | 2001-11-09 | 2006-03-21 | Via Tech Inc | Method for protecting phase lock loop in optical data-reading system |
WO2006124770A2 (en) * | 2005-05-13 | 2006-11-23 | The Feinstein Institute For Medical Research | Treatment of sepsis and inflammation with alpha2a adrenergic antagonists |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0071368A1 (de) * | 1981-07-28 | 1983-02-09 | Reckitt And Colman Products Limited | Imidazolinderivate |
US4855308A (en) * | 1987-12-04 | 1989-08-08 | Warner-Lambert Company | Method of treating senile cognitive decline with N'-substituted aminopyridine adrenergic agents |
EP0486385A1 (de) * | 1990-11-14 | 1992-05-20 | Adir Et Compagnie | Imidazol-Derivate, Verfahren zu deren Herstellung und diese enthaltende Zusammenstellungen |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4855385A (en) * | 1988-06-22 | 1989-08-08 | The Dow Chemical Company | Monocarboxylic acid derivatives of aliphatic based epoxy resins |
-
1993
- 1993-07-09 FR FR9308497A patent/FR2707166B1/fr not_active Expired - Fee Related
-
1994
- 1994-07-07 AT AT94921698T patent/ATE186640T1/de not_active IP Right Cessation
- 1994-07-07 PT PT94921698T patent/PT707477E/pt unknown
- 1994-07-07 US US08/581,516 patent/US5661172A/en not_active Expired - Fee Related
- 1994-07-07 JP JP50386595A patent/JP3494651B2/ja not_active Expired - Fee Related
- 1994-07-07 NZ NZ268914A patent/NZ268914A/xx unknown
- 1994-07-07 EP EP94921698A patent/EP0707477B1/de not_active Expired - Lifetime
- 1994-07-07 DE DE69421705T patent/DE69421705T2/de not_active Expired - Fee Related
- 1994-07-07 WO PCT/FR1994/000841 patent/WO1995001791A2/fr active IP Right Grant
- 1994-07-07 ES ES94921698T patent/ES2140544T3/es not_active Expired - Lifetime
- 1994-07-07 DK DK94921698T patent/DK0707477T3/da active
- 1994-07-07 AU AU72308/94A patent/AU688346B2/en not_active Ceased
- 1994-07-07 CA CA002166781A patent/CA2166781A1/fr not_active Abandoned
-
2000
- 2000-02-02 GR GR20000400227T patent/GR3032531T3/el not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0071368A1 (de) * | 1981-07-28 | 1983-02-09 | Reckitt And Colman Products Limited | Imidazolinderivate |
US4855308A (en) * | 1987-12-04 | 1989-08-08 | Warner-Lambert Company | Method of treating senile cognitive decline with N'-substituted aminopyridine adrenergic agents |
EP0486385A1 (de) * | 1990-11-14 | 1992-05-20 | Adir Et Compagnie | Imidazol-Derivate, Verfahren zu deren Herstellung und diese enthaltende Zusammenstellungen |
Non-Patent Citations (6)
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2752163A1 (fr) * | 1996-08-12 | 1998-02-13 | Pf Medicament | Utilisation de l'efaroxan pour la fabricaton de medicament destine au traitement de la maladie de huntington |
WO1998006393A1 (fr) * | 1996-08-12 | 1998-02-19 | Pierre Fabre Medicament | Utilisation de l'efaroxan pour la fabrication de medicament destine au traitement de la maladie de huntington |
US6153638A (en) * | 1996-08-12 | 2000-11-28 | Pierre Fabre Medicament | Use of efaroxan for producing medicine for treating huntington 's disease |
US8188126B2 (en) | 2002-05-16 | 2012-05-29 | Pierre Fabre Medicament | Imidazolic compounds and use thereof as alpha-2 adrenergic receptors |
Also Published As
Publication number | Publication date |
---|---|
AU7230894A (en) | 1995-02-06 |
FR2707166A1 (fr) | 1995-01-13 |
US5661172A (en) | 1997-08-26 |
PT707477E (pt) | 2000-04-28 |
DE69421705T2 (de) | 2000-06-29 |
AU688346B2 (en) | 1998-03-12 |
EP0707477A1 (de) | 1996-04-24 |
EP0707477B1 (de) | 1999-11-17 |
ATE186640T1 (de) | 1999-12-15 |
JP3494651B2 (ja) | 2004-02-09 |
ES2140544T3 (es) | 2000-03-01 |
DE69421705D1 (de) | 1999-12-23 |
FR2707166B1 (fr) | 1995-09-29 |
DK0707477T3 (da) | 2000-05-15 |
NZ268914A (en) | 1999-06-29 |
CA2166781A1 (fr) | 1995-01-19 |
JPH08512305A (ja) | 1996-12-24 |
GR3032531T3 (en) | 2000-05-31 |
WO1995001791A3 (fr) | 1995-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0678023B1 (de) | Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen | |
KR20030019455A (ko) | 수면 장애를 위한 가바펜틴 유사체 | |
HUE035105T2 (en) | A composition comprising nicotine and opipramole and its use | |
FR2837706A1 (fr) | Utilisation d'un antagoniste des recepteurs aux cannabinoides cb1 pour la preparation de medicaments utiles pour traiter les dysfonctionnements sexuels et/ou ameliorer les performances sexuelles | |
EP0707477B1 (de) | Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen | |
BE897058A (fr) | Utilisation d'un derive du spiro-succinimide dans le traitement de la demence du type alzheimer | |
US20020147206A1 (en) | Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy | |
EP0305276A2 (de) | Verwendung von 2-Amino-6-trifluormethoxybenzthiazol zur Herstellung eines Arzneimittels zur Behandlung von Schizophrenie | |
FR2619713A1 (fr) | Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement des troubles du sommeil et de la depression | |
FR2579893A1 (de) | ||
EP2146714B1 (de) | Verwendung von 4-cyclopropylmethoxy-n-(3,5-dichlor-1-oxidopyridin-4-yl)-5-(methoxy-)pyridin-2-carboxamid zur behandlung motorischer störungen aufgrund der parkinsonschen krankheit | |
US5948806A (en) | Treatment of Parkinson's disease with (+)2-(ethyl-2,3-dihydrobenzofuranyl)-2-Imidazoline (dexefaroxan or (+) efaroxan) | |
FR2705569A1 (fr) | Composition pharmaceutique à base d'une imidazolylcarbazolone destinée à l'administration rectale. | |
JPH07196509A (ja) | イソキノリン誘導体を含有する医薬組成物 | |
EP0489640B1 (de) | Verwendung von Phenyläthanolaminotetralinen zur Herstellung eines antidepressiven und Antistress-Arzneimittels | |
SE502323C2 (sv) | Användning av N-(2-hydroxietyl)nikotinamidnitrat eller ett farmaceutiskt godtagbart salt därav för framställning av ett läkemedel aktivt för behandling av sjukdomar förbundna med cerebral ischemi | |
CA2153399A1 (fr) | Utilisation de l'idazoxan et ses derives pour le traitement de demence senile du type alzheimer | |
BE881717A (fr) | Medicament a base d'un compose heterocyclique bicyclique condense | |
EP2131842A2 (de) | Verwendung eines verbundantagonisten des nk-2-rezeptors für ein neurokinin zur herstellung von medikamenten zur verhinderung und behandlung sexueller dysfunktion | |
CN117088862A (zh) | 一种硫代色元酮衍生物和应用 | |
LU87777A1 (fr) | Nouvelle forme galenique orale ameliorant la biodisponibilite | |
BE856652A (fr) | Composition pharmaceutique pour le traitement des troubles du sommeil | |
FR2585573A1 (fr) | Medicament pour prevenir l'abus d'alcool | |
WO1998006393A1 (fr) | Utilisation de l'efaroxan pour la fabrication de medicament destine au traitement de la maladie de huntington | |
BE882610A (fr) | Nouvelles compositions pharmaceutiques a base d'une quinazolinone exercant une action analgesique et d'un agent myotonolytique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA JP NZ US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA JP NZ US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2166781 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1994921698 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08581516 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 268914 Country of ref document: NZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1994921698 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1994921698 Country of ref document: EP |